A trial looking at DTP3 for lymphoma or myeloma

Cancer type:

Blood cancers
High grade lymphoma
Non-Hodgkin lymphoma




Phase 1/2

This trial is looking at a new drug called DTP3 for diffuse large B cell lymphoma or myeloma.

It is for people whose treatment has stopped working or their cancer has got worse.

More about this trial

There are a number of ways to treat diffuse large B cell lymphoma or myeloma. Myeloma is also called multiple myeloma. 

Sometimes the cancer comes back after treatment or treatment stops working. Doctors are looking at new treatments to help these groups of people. In this trial, they are looking at a new drug called DTP3.
DTP3 is a targeted cancer drug Open a glossary item. It aims to kill myeloma or lymphoma cells without affecting normal cells. It might have fewer side effects.                    

The main aims of the trial are to:

  • find the best dose of DTP3
  • learn what the side effects are
  • find out what happens to DTP3 in the body
  • find out how well DTP3 works

Who can enter

The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you. 

Who can take part

For people who have myeloma the following must apply. You:

  • have myeloma that is stage 1, stage 2 or stage 3 that needs to be treated
  • have myeloma that the doctor can measure in a blood or urine test
  • have myeloma that got worse after your last treatment or treatment stopped working 
  • have already had treatment that included bortezomib, lenalidomide or thalidomide, daratumumab or similar drugs. You might be able to take part if you had only 2 of these treatments. Your doctor will talk to you about this.
  • have had at least 2 different courses of treatment Open a glossary item in the past

For people who have diffuse large B cell lymphoma the following must apply. You:

  • have diffuse large B cell lymphoma that needs treatment 
  • have a type of lymphoma called non germinal large B cell lymphoma. This only applies to people joining the dose expansion group.
  • have at least 2 areas of lymphoma that your doctor can see on a scan that measure more than 1.5cm in length. Or you have one area that measures more than 2cm in length.
  • have no standard treatment Open a glossary item available to you
  • have lymphoma that got worse after your last treatment or treatment stopped working 

As well as the above entry conditions for myeloma and lymphoma, the following must also apply. You:

  • have satisfactory blood test results 
  • are up and about more than half the day, you can look after yourself but might not be able to work (performance status 0, 1 or 2)
  • are willing to use reliable contraception during the trial and for a period after if there is any chance you or your partner could become pregnant 
  • are at least 16 years old 

Who can’t take part

Cancer related 
You cannot join this trial if any of these apply. You:

  • have lymphoma of the brain or spinal cord
  • have T-cell histiocyte-rich large B-cell lymphoma
  • have a rare type of blood cancer called plasma cell leukaemia (plasma cell myeloma)
  • have primary amyloidosis. Open a glossary itemYour doctor will know this. 
  • have had treatment for myeloma or diffuse B cell lymphoma within 28 days of the first dose of DTP3. This doesn’t include having bisphosphonates. Open a glossary item
  • are suitable to have a stem cell transplant Open a glossary item or CAR T-cell therapy
  • have had a stem cell transplant or CAR T-cell therapy within 12 weeks of joining the trial
  • have taken part in another trial with an experimental drug within 28 days of joining this trial or you are having treatment with an experimental drug
  • have had radiotherapy within 28 days or might need to have radiotherapy while you are taking part in this trial. You can take part if you are having radiotherapy to a single area to help with symptoms Open a glossary item
  • have had another cancer in the past. You can join if you had successfully treated non melanoma skin cancer Open a glossary item, carcinoma in situ Open a glossary item of the cervix or early prostate cancer. You could join if you had another cancer in the last 3 years and there have been no signs of it since.

Medical conditions
You cannot join this trial if any of these apply. You:

  • have had a heart attack, significant heart surgery in the last 6 months or any other heart problem Open a glossary item that needs treatment. The trial team check if you have a heart condition before you join the trial.
  • have had a stroke or problems with reasoning, planning, judgment, memory and other thought processes (vascular dementia)
  • have a condition called POEMS syndrome 
  • have a risk of bleeding or you have a bleeding problem
  • have moderate to severe tingling and numbness or pain in your hands and feet (peripheral neuropathy Open a glossary item)
  • are having treatment that damps down the immune system Open a glossary item. This includes steroids unless it is a low dose or you are having them for a short time to control symptoms.
  • have HIV, an active hepatitis B or hepatitis C infection
  • have any other medical condition or mental health problem that the trial team think will affect you taking part 

You cannot join this trial if you are pregnant or breastfeeding.

Trial design

This is a phase 1/2 trial. The researchers would like up to 72 people across the UK to take part. This trial has 2 parts:

  • finding the best dose of DTP3 (dose escalation)
  • learning more about how the drug works (dose expansion)

Dose escalation 
The team need about 24 people with either myeloma or lymphoma to join the dose escalation part. The first few people taking part have a low dose of DTP3. The next few people have a higher dose if they don’t have any serious side effects. And so on, until doctors find the best dose. This dose is one that helps the most and has the fewest side effects

Dose expansion 
The researchers need about 24 people with myeloma and 24 with lymphoma to join this part. This part opens when they find the best dose in part 1. 

How you have treatment 
You have DTP3 as a drip into a vein. It takes about an hour each time. You have treatment three times a week on the hospital day care ward. This is likely to be on a Monday, Wednesday and Friday. The team can tell you more about this. Everyone has treatment for as long as it is working and the side effects aren’t too bad. 

Samples for research 
The researchers ask you to give some extra blood samples. Where possible, you have these at the same time as your routine blood tests. They also ask to look at samples of bone marrow Open a glossary item or samples of cancer tissue (biopsy Open a glossary item) your doctor may ask for.

They plan to use the samples to:

  • see how well DTP3 is working 
  • look at genes Open a glossary item in your cancer cells 
  • look for substances called biomarkers Open a glossary item to help work out why treatment might work for some people and not for others
  • measure DTP3 in the body

Hospital visits

You see the doctor and have tests before you can take part. These include:

After the first treatment, you may have an overnight stay in the hospital. This is so the team can take some blood samples to see what happens to DTP3 in the body. If you are unable to stay overnight, they take samples from you on the day care ward. These would stop at the end of the first day, to allow you to return home.

You have one extra bone marrow test or biopsy of cancer tissue. You have this during your third week of treatment. 

You have regular check ups and blood tests during treatment. 

Follow up
When you stop treatment, you see the team at your routine hospital appointments. This is to check how you are and if you have started another cancer treatment. 

The team phone you every 6 weeks to see how you are if you aren’t having hospital appointments. 

Side effects

The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better. 
Only a few people have had DTP3 in the past and in this study. So the team are not sure what the side effects are. You see the doctor regularly to see if there are any side effects. We’ll add information about these when we know more. 



Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Aris Chaidos

Supported by

Imperial College London
Institute of Cancer Research (ICR)
Medical Research Council (MRC)

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think